CD82 and melanoma: In this present study, we retrieved the melanoma tissue microarray clinical data for seven previously reported independent prognostic biomarkers [26-32], performed statistical analysis, and identified a molecular signature (loss of both KAI1 and p27) that defined a metastatic-like-subgroup (ML) among patients with primary melanomas, in both the training dataset and in a validation dataset.